The prolonged existence of COVID-19 has created a huge demand for effective therapeutic drugs.
Remdesivir was given FDA approval as an anti-coronavirus medicine, but despite speeding up recovery time for patients who had recently got COVID-19, Remdesivir did not improve survival rates. Several monoclonal antibodies that have decreased hospitalizations and deaths in COVID-19 patients were also given emergency use authorization by the FDA, but their efficacy has been reduced or even lost since the emergence of the new mutant Omicron.
Two oral anti-coronavirus drugs, Paxlovid from Pfizer and Molnupiravir from Merck, which have been shown to lower the risk of hospitalization and death in patients with Covid-19, were also given emergency use authorization by the FDA in December 2021. The impact is substantial, but there is still a lack of convincing proof that they can stop the spread of new coronavirus infections. Paxlovid has tolerability issues in some populations, and Molnupiravir has potential carcinogenicity issues in human cells.
Therefore, developing new strategies to control Covid-19 infection remains a top priority.
A study titled "Cas13d knockdown of lung protease CTSL prevents and treats SARS-CoV-2 infection" was published in the journal Nature Chemical Biology on July 25, 2022 by the teams of Professors Qianben Wang from Duke University, Shansu Liu from Ohio State University, and Yizhou Dong.
This study is the first to demonstrate that CRISPR-Cas13d (CasRx) can be used to prevent and treat COVID-19 infection. Specifically, the study used improved lung-targeting lipid nanoparticles to deliver CRISPR-Cas13d mRNA, specifically knocking down the mRNA of the CTSL gene in the lungs, thereby blocking the infection of SARS-CoV-2, and can also be used to treat SARS-CoV-2 infection.
In addition to offering a brand-new approach to preventing and treating COVID-19, the method is also effective regardless of how the virus mutates because it does not depend on the identification of particular viral structures.
The corresponding author of the paper, Professor Qianben Wang of the Department of Pathology at Duke University School of Medicine, said the results of this study suggest that CRISPR technology represents a unique strategy to control SARS-CoV-2 infection and should be used as a potential treatment approach.
In this latest paper, the research team used CRISPR-Cas13d (CasRx)-based RNA knockdown technology to deliver the mRNA form of the CRISPR-Cas13d system via lipid nanoparticles (LNPs) to achieve transient knockdown of cathepsin L (CTSL) gene mRNA effect. Since CTSL is primarily found in the lungs, the research team created a lung-selective nano-delivery system based on MC3 and adjusted the ratio of cationic liposomes on the basis of SORT-LNP in order to specifically deliver CRISPR-Cas13d mRNA to the lungs.
Professor Daniel Siegwart's lab at the University of Texas Southwestern Medical Center is where SORT-LNP was created. The organ-targeting specificity of LNPs in vivo can be altered and mRNA-targeted delivery to organs other than the liver is made possible by the addition of a fifth component, SORT lipids. This SORT-LNP can be extended to a variety of extrahepatic organs and tissues to achieve mRNA delivery to lung, kidney, and even epithelial and immune cells.
Using this improved lung-selective nano-delivery system, the research team successfully targeted the delivery of Cas13d (CasRx) mRNA/gRNA to the lung, achieving efficient, specific, and safe knockdown of the mRNA of the lung CTSL gene. The mRNA of the CTSL gene significantly reduced CTSL in the lungs. This can not only prevent SARS-CoV-2 from entering and infecting host cells to realize prevention, but also achieve significant results in the COVID-19 treatment.
According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is estimated to hit $75.3 billion by 2028, registering a CAGR of 4.8% from 2021 to 2028.
The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.Shift in consumer preference from synthetic to bio-based ingredients and development in biotechnology fuel the growth of the global biotech ingredients market.
On the other hand, limited availability of raw materials restrains the growth to some extent.
However, favorable government policies and technological advancements in bio-engineering are expected to create lucrative opportunities in the industry.Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/11710COVID-19 scenario-The outbreak of the pandemic has given way to either closure or suspension of production activities in most industrial units across the globe, which has impacted the market negatively.Nevertheless, initiation of mass vaccination in most countries is projected to mend the global situation and market is expected to get back on track soon.The global biotech ingredients market is analyzed across type, product, expression systems, and region.
The biosimilars segment, on the other hand, would exhibit the fastest CAGR of 5.0% during the forecast period.Based on product, the monoclonal antibodies segment contributed to more than one-fifth of the total market revenue in 2020 and is expected to dominate by 2028.
However, the hormones and growth factors segment would cite the fastest CAGR of 5.5% during from 2021 to 2028.Get Detailed COVID-19 Impact Analysis on the Biotech Ingredients Market: https://www.alliedmarketresearch.com/request-for-customization/11710?reqfor=covidBased on region, Europe held the major share in 2020, garnering nearly two-fifths of the global market.
